PIK3CA and hepatocellular carcinoma: Moreover, previous studies have also shown that PI3K inhibition sensitizes CSCs to chemotherapy and molecular targeted therapy in several cancers including leukemia, hepatocellular carcinoma and breast cancer [51-53].